The QuantiDNA™ DNA Measurement Assay is a cell-free DNA (cfDNA) quantification method. The assay uses direct cfDNA quantification without DNA extraction or qPCR to quantify human cfDNA from plasma. The method uses DNA-hybridization-based, modified branched DNA (bDNA) technology. The target DNA is captured through DNA hybridization and the signals associated with the quantity of the target DNA, rather than the target by itself, are amplified and quantified by a luminometer.

  • Measures plasma Cell Free DNA (cfDNA) that exists in circulation.
  • cfDNA circulates in the body and induces patients to develop micro-metastases (Volekmar et al. 2018).
  • cfDNA concentration has higher sensitivity and specificity than the conventional tumor markers such as CEA, CA19-9 and CA 72–4 (Valpione et al. 2018).
  • cfDNA levels in cancer patients, including Gastric Cancer are higher than in healthy subjects (Yu et al. 2019; Miao et al. 2019; Zhong et al. 2020), suggesting that plasma cfDNA can be used as a biomarker to indicate tumor disease status

cfDNA as a marker in NSLC, Breast Cancer and monitor efficacy of Chemotherapy in Gastric Cancer and other cancer types

  • Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool
  • Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer
  • Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer Healthy individuals: 12.28 ± 7.72 ng/mL; Advanced gastric cancer patients: 29.52 ± 21.64 ng/mL
  • Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis Oncotarget, 2017, Vol. 8, (No. 60), pp: 102336-102345